Edinburgh Biosciences has reported encouraging early outcomes from a structured long-term safety and performance follow-up ...
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, ...
Ten years after undergoing bariatric surgery as teens, over half of study participants demonstrated not only sustained weight loss, but also resolution of obesity-related conditions, such as type 2 ...
One of the world's most extensive birth cohorts is now entering later adulthood. At the University of Oulu in Finland, the ...
Biofrontera announced that a key milestone in its Phase 3 study of the use of Ameluz and RhodoLED PDT in the treatment of sBCC was met with the last patient completing the 1 year follow-up visit in ...
About 40% of patients with diagnosed heart failure did not pursue future cardiology consultations, regardless of the initial severity of their condition. A single ...
Adequate outpatient follow-up within 30 days significantly reduces 30-day all-cause hospital readmissions, impacting hospital finances and patient care quality. The study analyzed 83 studies, ...
We conducted 28 semistructured in-depth interviews with 12 women with an abnormal CBE at the primary health facility who did not have diagnostic follow-up, four community health workers, nine health ...
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results